L-DOS47

P1/2, N=28, Active, not recruiting, Helix BioPharma Corporation | Recruiting --> Active, not recruiting | N=20 --> 28 | Trial completion date: Aug 2025 --> Nov 2024

P1, N=14, Terminated, Helix BioPharma Corporation | Completed --> Terminated; Slow enrolment - standard of care evolved over the duration of the study such that treatment regimen employed in the study was no longer current standard of care for first line resulting in recruitment challenges.

Using chemical exchange saturation transfer-magnetic resonance imaging (CEST-MRI) to measure the tumor extracellular pH (pHe), we confirmed that L-DOS47 raises the tumor pHe from 4 h to 96 h post injection in acidic tumors (average increase of 0.13 units). Additional studies showed that combining L-DOS47 with anti-PD1 significantly increases the efficacy of the anti-PD1 monotherapy, reducing tumor growth for up to 4 weeks.

P1/2, N=20, Recruiting, Helix BioPharma Corporation | Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2024

There was an apparent association between best overall response rate and highest anti-L-DOS47 antibody titer measured. L-DOS47 combined with standard pemetrexed and carboplatin chemotherapy is well tolerated in patients with recurrent or metastatic nonsquamous NSCLC at doses up to 9.0 μg/kg.

P1, N=14, Completed, Helix BioPharma Corporation | Recruiting --> Completed | N=40 --> 14 | Trial completion date: Oct 2020 --> Sep 2019 | Trial primary completion date: Oct 2020 --> Aug 2019